The FDA accepted a Priority Review BLA for RP1 and Opdivo in advanced melanoma, with a PDUFA date of July 22, 2025. The BLA is supported by IGNYTE trial data, focusing on patients with anti-PD-1 ...

Opdivo/Yervoy has been approved since 2018 as first-line treatment for patients with intermediate- and poor-risk advanced RCC, and BMS was hoping to extend the use of the regimen into patients ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for subcutaneous use to treat various solid tumours. This new combination product ...

Opdivo plus chemotherapy improved median OS to 14.4 months versus 11.1 months in patients with PD-L1 CPS ≥5. The 5-year OS rates were 16% for Opdivo plus chemotherapy and 6% for chemotherapy alone in ...

Please provide your email address to receive an email when new articles are posted on . Opdivo was previously only available intravenously. The approval comes after CHECKMATE-67T study results.